12:00-12:55 PT

Welcome
Dr. Luca Quagliata, PhD, BCMAS, COA; Vice President and Global Head of Medical Affairs, Thermo Fisher Scientific

Introduction to liquid biopsies for precision oncology: Current status of oncology biomarker testing needs from the clinical perspective
Dr. Simon Heeke, PhD; Head of Liquid Biopsy Translational Group, Assistant Professor, Thoracic Head and Neck Oncology, MD Anderson Cancer Center, Houston, Texas, USA

Reimbursement for liquid biopsy in the United States: Understanding recent changes and the implications
Mr. Charles Mathews, MPP; Partner, ClearView HealthCare Partners

Live Q&A

12:00–13:15 SGT

Welcome
Dr.Luca Quagliata, PhD, BCMAS, COA; Vice President and Global Head of Medical Affairs, Thermo Fisher Scientific

Experience with Rapid NGS in solid tumor genomic profiling
Dr. Omshree Shetty , PhD; Assistant Professor and Scientific Officer, National Coordinator for Molecular Pathology Quality Assurance Program, Tata Memorial Hospital, Mumbai, India

Introduction to liquid biopsies for precision oncology: A focus on treatment selection and monitoring in late stages
Dr. Simon Heeke, PhD; Head of Liquid Biopsy Translational Group, Assistant Professor, Thoracic Head and Neck Oncology, MD Anderson Cancer Center, Houston, Texas, USA

SGT implementation of an ISO 15189-accredited next-generation sequencing service for cell-free total nucleic acid (cfTNA) analysis: The experience of a clinical diagnostic laboratory
Ms. Amy Connolly, MSc; Specialist Medical Scientist, Histopathology Department Cork University Hospital, Cork, Ireland

Live Q&A

12:55-13:50 PT

Oncomine Clinical Research Grants: Supporting clinical oncology research
Dr. Jose Luis Costa, PhD, BCMAS; Global Director, Scientific Affairs, Thermo Fisher Scientific

Analysis of central nervous system tumor ctDNA from cerebrospinal fluid
Dr. Leomar Ballester, MD, PhD; Assistant Professor, Department of Pathology and Laboratory Medicine, MD Anderson Cancer Center

HRD assessment using Oncomine Comprehensive Assay Plus
Dr. Elaine Wong Ho, PhD; Senior Product Manager, Oncology, Thermo Fisher Scientific

Live Q&A

13:15-14:15 SGT

Measurable Residual Disease (MRD) research in AML using Oncomine^TM NGS analysis​
Dr. Jong-Mi Lee, MD, PhD; Assistant Professor, College of Medicine, The Catholic University of Korea, Seoul, South Korea

Oncomine Clinical Research Grants: Supporting clinical oncology research
Dr. Jose Luis Costa, PhD, BCMAS; Global Director, Scientific Affairs, Thermo Fisher Scientific

HRD assessment using Oncomine Comprehensive Assay Plus
Dr. Elaine Wong Ho, PhD; Senior Product Manager, Oncology, Thermo Fisher Scientific

Live Q&A

15:00-15:55 CEST

Welcome
Luca Quagliata, PhD, BCMAS, COA; Vice President and Global Head of Medical Affairs, Thermo Fisher Scientific

Implementation of an ISO 15189-accredited next-generation sequencing service for cellfree total nucleic acid (cfTNA) analysis: The experience of a clinical diagnostic laboratory
Ms. Amy Connolly, MSc; Specialist Medical Scientist, Histopathology Department, Cork University Hospital, Cork, Ireland

B-cell receptor clonality assessment using next generation sequencing in gastric mucosa-associated lymphoid tissue lymphoma
Dr. Rer. Nat. Chidimma Akpa; Senior Associate, Department of Hematology, Oncology, and Cancer Immunology, Charité Universitätsmedizin Berlin, Germany

Live Q&A

15:55-17:25 CET

Oncomine clinical research grants: Supporting clinical oncology research
Dr. Jose Luis Costa, PhD, BCMAS; Global Director, Scientific Affairs, Thermo Fisher Scientific

Evaluation of Oncomine Comprehensive Assay Plus NGS Panel and OncoScan CNV Assay for homologous recombination deficiency detection
Dr. Lone Schejbel, PhD; Molecular Biologist, Department of Pathology, Herlev and Gentofte Hospital, Denmark

Live Q&A

16:35-16:45 - BREAK

HRD assessment using Oncomine Comprehensive Assay Plus
Dr. Elaine Wong Ho, PhD; Senior Product Manager, Oncology, Thermo Fisher Scientific

Rapid genomic profiling of lymphoid malignancies
Mr. Robert Baker, BSc, MIBMS; Molecular Haematology Operational Manager, Health Services Laboratories LLP, United Kingdom

Live Q&A

17:25-18:20 CET

Johnson & Johnson Strategy in Precision Medicine
Dr. Leonie de Visser, PhD; : Portfolio and Alliance Lead- Precision Medicine EMEA Strategy and Operations, Johnson &Johnson Innovative Medicine

Innovative Medicine Experience and impact of clinical oncology diagnostics using Oncomine Dx Express Test
Dr hab. n. med. Bartłomiej Budny; Head of Department of Cancer Molecular Diagnostics, Wielkopolska Center of Pulmonology and Thoracic Surgery of Eugenia and Janusz Zeyland, Poland

Live Q&A